abrocitinib   Click here for help

GtoPdb Ligand ID: 9991

Synonyms: Cibinqo® | compound 25 [PMID: 29298069] | PF-04965842 | PF04965842
Approved drug PDB Ligand Immunopharmacology Ligand
abrocitinib is an approved drug (UK, Japan & EMA (2021), FDA (2022))
Compound class: Synthetic organic
Comment: Abrocitinib (PF-04965842) is a JAK inhibitor [4]. X-ray crystal structures of PF-04965842 bound to both JAK1 and JAK2 have been deposited with the Protein DataBank (accession IDs 6BBU and 6BBV respectively). We used the SMILES string supplied with the article in which the structure was declared [4] to generate our representation of the chemical structure. The IUPAC name in abrocitinib's INN record resolves to the same StdInChIKey as our structure. PubChem CID 78323835 represents the structure without specified stereochemistry.
The JAKs are immunokinases that are molecular targets of therapeutics which are used in the treatment of immune-mediated diseases.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 99.36
Molecular weight 323.14
XLogP 2.05
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CCCS(=O)(=O)NC1CC(C1)N(c1ncnc2c1cc[nH]2)C
Isomeric SMILES CCCS(=O)(=O)N[C@@H]1C[C@@H](C1)N(c1ncnc2c1cc[nH]2)C
InChI InChI=1S/C14H21N5O2S/c1-3-6-22(20,21)18-10-7-11(8-10)19(2)14-12-4-5-15-13(12)16-9-17-14/h4-5,9-11,18H,3,6-8H2,1-2H3,(H,15,16,17)/t10-,11+
InChI Key IUEWXNHSKRWHDY-PHIMTYICSA-N
No information available.
Summary of Clinical Use Click here for help
Abrocitinib (PF-04965842) was advanced to clinical trials for autoimmune conditions, and reached Phase 3 evaluation for atopic dermatitis and Phase 2 for plaque psoriasis (NCT02201524). Results from the psoriasis trial have been published [1], and these indicated that PF-04965842 improved disease symptoms and was well tolerated in patients with moderate to severe psoriasis. Further development for psoriasis has been terminated by the sponsor (Pfizer) for business reasons. Development in moderate to severe atopic dermatitis is continuing in Pfizer's JAK1 Atopic Dermatitis Efficacy and Safety (JADE) program, which incluides the JADE MONO-1 (NCT03349060) and JADE MONO-2 (NCT03575871) trials. Results demonstrating significant efficacy in the JADE MONO-1 study were published in July 2020 [3], and similarly supportive results from JADE MONO-2 followed in August 2020 [2].

Abrocitinib was first approved for clinical use in 2021. Under these authorisations it is indicated as a treatment for moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. The FDA's approval as a treatment for atopic dermatitis was granted in January 2022.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02201524 Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis Phase 2 Interventional Pfizer
NCT03575871 Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis Phase 3 Interventional Pfizer
NCT03349060 Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis Phase 3 Interventional Pfizer This RCT is known as the 'JADE MONO-1' trial. Results published in 2020, indicated that once daily, oral abrocitinib for 12 weeks was effective and well tolerated in trial participants with moderate-to-severe atopic dermatitis. 3
External links Click here for help
For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
European Medicines Agency (EMA)